Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294970 | 0.85 | SCN9A (0.41) | TBXA2RSCN9A | |
| SCHEMBL6294722 | 0.85 | PYGL (0.42) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6294975 | 0.84 | PYGL (0.42) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6294962 | 0.83 | PYGL (0.40) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6294986 | 0.83 | PYGL (0.44) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6294677 | 0.82 | PYGL (0.45) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6294719 | 0.81 | PYGL (0.44) | PYGLTBXA2RALDH1A1MAPTMEN1 | |
| SCHEMBL6300671 | 0.80 | PYGL (0.38) | PYGLALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6300609 | 0.80 | PYGL (0.38) | PYGLTBXA2RALDH1A1MAPTSCN9A | |
| SCHEMBL6295779 | 0.77 | MERTK (0.42) | PYGLTBXA2RALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916837-B2 | Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them | EISAI CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1312602-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | Eisai Co., Ltd. (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | F2, SERPINC1, F12 | PYGL 1434/4885TBXA2R 10/4885ALDH1A1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.